Axogen, INC

Axogen, Inc. announced robust second quarter 2026 financial results, exceeding expectations and leading to an upward revision of full-year revenue guidance.

Axogen Inc. announced first quarter 2026 financial results, with revenue up 26.6% year-over-year to $61.5 million, and raised its full-year revenue guidance to at least 20% growth, targeting $270 million.

Axogen, Inc. announced robust fourth quarter and full-year 2025 financial results, highlighted by significant revenue growth, FDA approval for Avance, and positive 2026 financial guidance.

Axogen, Inc. announced the pricing of an upsized public offering of 4 million common shares at $31.00 each, aiming to raise $124 million to repay its term loan facility and for general corporate purposes.

Axogen, Inc. announced preliminary unaudited fourth quarter and full-year 2025 financial results, reporting significant revenue growth and the FDA approval of its Avance biologic.

Axogen, Inc. announced a 7% base salary increase and a higher target bonus for CFO Lindsey Hartley, alongside a new two-year post-employment non-competition agreement.

Axogen Inc. announced its financial results for the second quarter ended June 30, 2026, reporting a 23.1% increase in revenue compared to the prior year period.

Axogen Inc. reported a 26.6% increase in Q1 2026 revenue to $61.5 million, but its net loss widened to $19.6 million.

Axogen, Inc. reported a significant increase in third-quarter revenue and a shift to net income, alongside reduced net losses for the nine-month period, despite an FDA BLA review extension.

Axogen, Inc. reported a net income of $579,000 for the second quarter of 2025, a significant improvement from a net loss in the prior year, driven by an 18.3% increase in revenues.

Axogen, Inc. announces a 17.4% increase in revenue for the first quarter of 2025 and highlights progress in its Biologics License Application (BLA) for Avance Nerve Graft.

Axogen, Inc. announced a 17.9% increase in revenue for the third quarter of 2024 and the FDA's acceptance of their Biologics License Application (BLA) for Avance Nerve Graft.

Axogen, Inc. reported a 20.2% increase in revenue for 2025, driven by product volume and pricing, alongside FDA approval for its key Avance product.

Axogen's 2024 10-K filing reveals a revenue increase alongside ongoing efforts to secure FDA approval for its Avance Nerve Graft product.

Axogen, Inc. has awarded performance-based restricted stock units to an employee under its 2019 Long-Term Incentive Plan, with vesting contingent on performance goals and continued service.

Marc A Began, EVP & General Counsel of Axogen, Inc., sold 67,500 shares of common stock on August 10, 2026 for $47.34 per share.

Amy Mcbride Wendell, a Director of Axogen, Inc., sold 13,353 shares of common stock on August 11, 2026 for $48.42 per share.

Kathy Johnson Weiler, a Director of Axogen, Inc., sold 14,150 shares of common stock on August 7, 2026 for $45.30 per share.

Axogen, Inc. reports that Director William P. Burke received an annual equity grant of restricted stock units valued at $185,000.

Axogen, Inc. Director John Johnson was granted 4,392 restricted stock units as an annual equity award for his service.

Axogen, Inc. reports an annual equity grant to Director Alan M. Levine, valued at $185,000, vesting in one year.

Axogen, Inc. announced its 2026 Annual Meeting of Shareholders will be held virtually on June 23, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Axogen is asking shareholders to approve an amended long-term incentive plan to attract and retain talent, following a year of strong financial results and strategic advancements.

Axogen is asking shareholders to approve an increase in shares authorized for issuance under its long-term incentive plan to maintain competitive compensation during a period of significant leadership changes.

First Light Asset Management, LLC and Mathew P. Arens report increased beneficial ownership of Axogen, Inc. common stock, now holding approximately 7.58%.

Vanguard Capital Management has disclosed a beneficial ownership of 4.99% in Axogen Inc., holding 2,654,445 shares as of June 30, 2026.

First Light Asset Management and Mathew P. Arens report a combined beneficial ownership of 6.8% of Axogen Inc. common stock as of April 30, 2026.

Vanguard Capital Management reports beneficial ownership of over 2.6 million shares, representing 5.12% of Axogen Inc.'s common stock.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Axogen Inc. following an internal corporate realignment.

First Light Asset Management and Mathew P. Arens have increased their beneficial ownership in Axogen, Inc., now holding 12.24% and 12.88% respectively.